Is fenelidone a hormonal drug? Effects and side effects of kidney disease treatment

Finerenone is a new type of selective non-steroidal mineralocorticoid receptor antagonist (MRA). It is not a hormonal drug in the traditional sense, but a non-hormonal antagonist that targets mineralocorticoid receptors. Compared with traditional hormonal drugs such as spironolactone and eplerenone, fenelinone is significantly different in structure and mechanism of action, so it has better selectivity and fewer side effects. It is mainly used to treat patients with chronic kidney disease (CKD) accompanied by type 2 diabetes, and has significant renal and cardiovascular protective effects.

In the treatment of kidney disease, fenelidone has shown promising results. Patients with chronic kidney disease, especially those with diabetes, often have inflammation and fibrosis reactions, leading to continued deterioration of kidney function. Fennelidone slows the progression of kidney disease by selectively blocking mineralocorticoid receptors and attenuating aldosterone-mediated inflammation and fibrotic processes. Clinical studies have shown that long-term use of fenelidone can effectively reduce urine protein levels, delay the decline of eGFR (glomerular filtration rate), and significantly reduce the risk of end-stage renal function (such as dialysis or kidney transplantation). This makes it a new treatment option for patients with type 2 diabetes and proteinuria.

However, like all drugs, while the therapeutic benefits of fenelidone come with certain risks of side effects. The more common adverse reactions include hyperkalemia (increased potassium in the blood), hypotension, and mild fluctuations in renal function. In particular, hyperkalemia is a common side effect of using MRA drugs. If not monitored and managed, it may lead to risks such as arrhythmia. Therefore, while taking fenelidone, doctors usually recommend regular testing of blood potassium levels and renal function indicators so that the dose can be adjusted in time or necessary intervention measures can be taken. Compared with traditional MRA drugs, fenelidone has a lower probability of inducing breast hyperplasia, impotence and other hormone-related side effects, and has better safety.
Overall, the emergence of fenelidone provides a new treatment idea for patients with chronic kidney disease such as diabetic nephropathy. Its non-hormonal characteristics give it better receptor selectivity and lower risk of side effects, and it plays an important role in improving renal function, reducing proteinuria and cardiovascular complications. However, during use, patients still need to use the medication scientifically under the guidance of a doctor, and closely monitor changes in electrolytes and kidney function to ensure safety and effectiveness. At the same time, although fenelidone has been approved for use in many countries, it is still a relatively new drug in some areas. If patients need to know detailed drug purchase channels and medical insurance reimbursement status, it is recommended to consult the local hospital pharmacy or pharmaceutical service platform. With the continuous expansion of clinical applications, fenelidone is expected to play an increasingly important role in the field of renal disease treatment.
Reference: https://www.kerendia.com/